By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162



Company News
Agendia BV Co-Founder And CSO Develops Method To Identify Women Who Will Benefit From Tamoxifen Therapy For Breast Cancer 7/31/2014 10:59:07 AM
Agendia BV And CBLpath Announce Agreement To Assist Physicians In Diagnostic Assessment Of Breast Cancer 7/16/2014 8:39:05 AM
Agendia BV Release: Value Of Breast Cancer Molecular Subtyping Documented By Independent Study Comparing Genomic Tests At American Society of Clinical Oncology 2014 Meeting 6/10/2014 9:57:44 AM
Molecular Subtyping With Agendia BV Tests Can Provide Better Guidance For Breast Cancer Treatment, New Research Reports 5/7/2014 10:18:28 AM
Agendia BV Announces New Agreement With Daiichi Sankyo, Inc. (4568.t) To Support Oncology Drug Development 4/24/2014 7:58:18 AM
Agendia BV Co-Founder Will Receive EU Prize For Women Innovators 3/7/2014 8:38:18 AM
Agendia BV Announces Upcoming Presentation Of New Breast Cancer Data On Molecular Subtyping 2/27/2014 9:47:18 AM
Agendia's Mammaprint & Blueprint Tests For Breast Cancer Highlighted At Personalized Medicine Conference 1/30/2014 9:03:59 AM
Agendia BV Release: Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence 8/27/2013 9:30:36 AM
Agendia BV Release: Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers 6/3/2013 10:28:28 AM